Alpha Tau Medical Ltd. (DRTS), the developer of the Alpha DaRT platform, and Tolmar International Ltd. have entered into a strategic collaboration to develop and commercialize Alpha DaRT for the treatment of prostate cancer in the United States.
Prostate cancer remains the second-leading cause of cancer-related death among American men, with more than 330,000 new cases projected for this year. Existing surgical treatments often lead to long‑term complications such as erectile dysfunction and urinary incontinence, highlighting the urgent need for innovative alternatives.
Under the agreement, Tolmar will secure exclusive U.S. commercialization rights for prostate cancer indications for twenty years from the first commercial sale, with an option to expand into bladder cancer contingent upon the achievement of specified clinical milestones. Alpha Tau will manufacture Alpha DaRT for Tolmar’s U.S. commercialization, providing the product at a cost of 60 % of the onward net sales price.
Tolmar has committed an initial $15 million in manufacturing investment, a $20 million equity infusion at $11.99 per share, and up to $161.5 million in milestone payments tied to clinical, regulatory, and commercial achievements.
Alpha DaRT delivers highly potent alpha‑particle radiation directly within tumors, designed to eradicate cancer cells with precision while minimizing damage to surrounding healthy tissue. “This collaboration represents a significant step toward delivering Alpha DaRT to patients in the United States, leveraging Tolmar’s established commercial infrastructure in urology and oncology,” said Alpha Tau CEO Uzi Sofer. “The partnership aligns with Tolmar’s mission to expand innovative therapies in prostate cancer care,” added Tolmar CEO Anil D’Souza.
The agreement also designates joint responsibility for clinical development in prostate cancer; Tolmar will fund pivotal U.S. trials, while Alpha Tau will retain rights outside the United States for prostate and bladder cancer indications.
With this partnership, Alpha Tau and Tolmar aim to transform the U.S. uro‑oncology landscape by introducing a novel, localized therapy for prostate cancer patients.
![Lebanon Crisis Threatens Fragile US-Iran Ceasefire Agreement]](https://i3.wp.com/static01.nyt.com/images/2026/06/19/multimedia/19mideast-lebanon-fghc/19mideast-lebanon-fghc-facebookJumbo.jpg?w=1024&resize=1024,1024&ssl=1 "Lebanon Crisis Threatens Fragile US-Iran Ceasefire Agreement]")
